Q&A on the Johnson & Johnson COVID-19 vaccine with Mona Chitre, PharmD, Chief Pharmacy Officer and Vice President of Clinical Strategy and Innovation at Excellus BlueCross BlueShield

Posted on March 9, 2021

Dr. Chitre leads Excellus BlueCross BlueShield’s pharmacy strategy and is responsible for driving affordability, innovation and operational excellence. She completed her undergraduate and graduate training at Rutgers University and her post-doctoral primary care residency at the Buffalo VA Medical Center in Buffalo, New York.

Q: Dr. Chitre, the Johnson & Johnson (J&J) vaccine is the third COVID-19 vaccine being distributed in the U.S. Is it safe? Why do we need a third vaccine option?
A: All vaccines have the same goal – to protect us. The J&J vaccine was tested thousands of times to ensure safety and is authorized for use in the U.S. It’s important that everyone who wants the COVID-19 vaccine can receive it. In addition to the Moderna and Pfizer-BioNTech vaccines, the J&J vaccine is another way to help increase protection against the virus that causes COVID-19. Since all three vaccines are safe, the best vaccine is the one you have access to.

Q: How does the J&J vaccine differ from Moderna’s and Pfizer-BioNTech’s?
A: The J&J vaccine is a single dose which offers maximum protection quicker than Moderna’s and Pfizer-BioNTech’s vaccines. The J&J vaccine has proven to be 66% effective at preventing moderate to severe cases of COVID-19. With all three vaccine options, no fragment of the live virus is in the vaccine so the vaccine itself cannot make you sick with COVID-19.

Q: Should we be concerned with a less effective rate?
A: No, there is no need to be concerned. The only way to accurately compare the effectiveness of these vaccines is by direct comparison in head-to-head clinical trials, which did not happen across the three vaccine options. Testing took place in different regions, at different points in time, and with varying COVID-19 occurrences. It is best not to compare the effective rates between the vaccines.

The data proves that the J&J vaccine is 85% effective against severe COVID-19 cases, and 100% effective at preventing death from COVID-19. Based on the data, the J&J vaccine is a very safe and effective option.

Q: There is mention of a booster vaccine to help protect against the COVID-19 variants. What information is known or suggested about this?

A: Scientists are currently looking into if a booster dose is needed to address variants. It is emerging science at this time, but it is still recommended that you get your vaccine as soon as it is available for you.

Q: We know that vaccines were given to high-risk groups first. The data suggests that the number of deaths in nursing homes is going down by more than 60%. Do you feel this is because of the vaccine?
A: Absolutely. Nursing home residents were among the first people to receive the vaccine. The data shows how powerful the vaccines are against the virus, which is encouraging to hear. Reports like these make me so hopeful as the vaccines continue to rollout. I’m excited for my children to be reunited with their grandparents. I’m optimistic about the future.

Other Member News

M&T Bank Reminds Small Businesses of March 18 Deadline for New York State Retirement Savings Program
March 16, 2026

M&T Bank Reminds Small Businesses of March 18 Deadline for New York State Retirement Savings Program

Every business in New York State with 10 employees or more will soon be required to offer retirement savings plan options to their workfo

Nave's Neighbors Logo
March 16, 2026

Nave Law Firm Recognizes Reflections Management and Care as March’s Nave’s Neighbor

The Nave’s Neighbors program spotlights nonprofit and community organizations that strengthen the region through service, advocacy, and meaningful support.

2026 Ag Agency Awareness Day
March 15, 2026

2026 Ag Agency Awareness Day

This program is geared towards aspiring farmers, beginning farmers and established agricultural producers who are looking for information on how to improve or expand their agriculture business.

March 13, 2026

Upstate Biotech Ventures Overview

The session will include a discussion of eligibility and the application process as well as Excell Partners’ due diligence system for reviewing applications and the UBV pitch.

Historic Green Mansion in Syracuse to be Transformed into Headquarters for the Greater Syracuse Land Bank and Workforce Housing with Investment from NBT CEI-Boulos Impact Fund
March 12, 2026

Historic Green Mansion in Syracuse to be Transformed into Headquarters for the Greater Syracuse Land Bank and Workforce Housing with Investment from NBT CEI-Boulos Impact Fund

Redevelopment of Long-Vacant Historic Green Mansion by Local Developers Aims to Catalyze Revitalization of Near Westside Neighborhood.

Production Poster for A Bad Year for Tomatoes
March 12, 2026

A Bad Year for Tomatoes

Directed by William Allman, the production featured Rhoda Rosen, James Buerkel, Mary Anne Sheboy and Irma Lange.

photo of Hancock Estabrook attorney Alec M. Savage
March 11, 2026

Alex M. Savage Joins Hancock Estabrook, LLP

He is a graduate of St. Lawrence University and Syracuse University College of Law, where he served as an Executive Editorial member of the Syracuse Law Review.

nypa pic
March 11, 2026

The 2026 NYPA & NYS Canal Corporation Supplier Diversity Expo Is Back!

This year’s theme, “Energizing New York’s Economy,” reflects more than a message; it reflects how the Expo has evolved. 

OCO Weekly Menu for March 16-20
March 11, 2026

View Oswego County Opportunities Weekly Menu for March 16-20

Come enjoy nutritious meals and spend time with friends. Everyone is welcome!